Cargando…
BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
Since the initial discovery that a subset of patients with cutaneous melanoma harbor BRAF mutations, substantial research has been focused on determining the pathologic consequences of BRAF mutations, optimizing diagnostic techniques to identify these mutations, and developing therapeutic interventi...
Autores principales: | Sullivan, Ryan J., Flaherty, Keith T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235817/ https://www.ncbi.nlm.nih.gov/pubmed/22175026 http://dx.doi.org/10.1155/2011/423239 |
Ejemplares similares
-
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014) -
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
por: Shen, Che-Hung, et al.
Publicado: (2016) -
Overexpression of Mcl-1 confers resistance to BRAF(V600E) inhibitors alone and in combination with MEK1/2 inhibitors in melanoma
por: Fofaria, Neel M., et al.
Publicado: (2015) -
Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma
por: Romano, David, et al.
Publicado: (2022) -
Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)